170 related articles for article (PubMed ID: 38263353)
1. Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program.
King B; Soung J; Tziotzios C; Rudnicka L; Joly P; Gooderham M; Sinclair R; Mesinkovska NA; Paul C; Gong Y; Anway SD; Tran H; Wolk R; Zwillich SH; Lejeune A
Am J Clin Dermatol; 2024 Mar; 25(2):299-314. PubMed ID: 38263353
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of ritlecitinib in adolescents with alopecia areata: Results from the ALLEGRO phase 2b/3 randomized, double-blind, placebo-controlled trial.
Hordinsky M; Hebert AA; Gooderham M; Kwon O; Murashkin N; Fang H; Harada K; Law E; Wajsbrot D; Takiya L; Zwillich SH; Wolk R; Tran H
Pediatr Dermatol; 2023; 40(6):1003-1009. PubMed ID: 37455588
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b-3 trial.
King B; Zhang X; Harcha WG; Szepietowski JC; Shapiro J; Lynde C; Mesinkovska NA; Zwillich SH; Napatalung L; Wajsbrot D; Fayyad R; Freyman A; Mitra D; Purohit V; Sinclair R; Wolk R
Lancet; 2023 May; 401(10387):1518-1529. PubMed ID: 37062298
[TBL] [Abstract][Full Text] [Related]
4. A plain language summary on ritlecitinib treatment for adults and adolescents with alopecia areata.
King B; Zhang X; Harcha WG; Szepietowski JC; Shapiro J; Lynde C; Mesinkovska NA; Zwillich SH; Napatalung L; Wajsbrot D; Fayyad R; Freyman A; Mitra D; Purohit V; Sinclair R; Wolk R
Immunotherapy; 2023 Oct; 15(14):1093-1103. PubMed ID: 37403610
[TBL] [Abstract][Full Text] [Related]
5. A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results.
King B; Guttman-Yassky E; Peeva E; Banerjee A; Sinclair R; Pavel AB; Zhu L; Cox LA; Craiglow B; Chen L; Banfield C; Page K; Zhang W; Vincent MS
J Am Acad Dermatol; 2021 Aug; 85(2):379-387. PubMed ID: 33757798
[TBL] [Abstract][Full Text] [Related]
6. Ritlecitinib and brepocitinib demonstrate significant improvement in scalp alopecia areata biomarkers.
Guttman-Yassky E; Pavel AB; Diaz A; Zhang N; Del Duca E; Estrada Y; King B; Banerjee A; Banfield C; Cox LA; Dowty ME; Page K; Vincent MS; Zhang W; Zhu L; Peeva E
J Allergy Clin Immunol; 2022 Apr; 149(4):1318-1328. PubMed ID: 34863853
[TBL] [Abstract][Full Text] [Related]
7. Ritlecitinib: an investigational drug for the treatment of moderate to severe alopecia areata.
Eisman S; Sinclair R
Expert Opin Investig Drugs; 2021 Dec; 30(12):1169-1174. PubMed ID: 34826225
[TBL] [Abstract][Full Text] [Related]
8. LITFULO
Gupta AK; Ravi SP; Vincent K; Abramovits W
Skinmed; 2023; 21(6):434-438. PubMed ID: 38051245
[TBL] [Abstract][Full Text] [Related]
9. Characterizing the relationships between patient-reported outcomes and clinician assessments of alopecia areata in a phase 2a randomized trial of ritlecitinib and brepocitinib.
Winnette R; Banerjee A; Sikirica V; Peeva E; Wyrwich K
J Eur Acad Dermatol Venereol; 2022 Apr; 36(4):602-609. PubMed ID: 35000236
[TBL] [Abstract][Full Text] [Related]
10. Hair Loss Profiles and Ritlecitinib Efficacy in Patients with Alopecia Areata: Post Hoc Analysis of the ALLEGRO Phase 2b/3 Study.
Thaçi D; Tziotzios C; Ito T; Ko J; Karadağ AS; Fang H; Edwards RA; Bonfanti G; Wolk R; Tran H; Law E
Dermatol Ther (Heidelb); 2023 Nov; 13(11):2621-2634. PubMed ID: 37707764
[TBL] [Abstract][Full Text] [Related]
11. Integrated safety analysis of baricitinib in adults with severe alopecia areata from two randomized clinical trials.
King B; Mostaghimi A; Shimomura Y; Zlotogorski A; Choi GS; Blume-Peytavi U; Passeron T; Holzwarth K; Dutronc Y; McCollam J; Yang FE; Stanley S; Wu WS; Sinclair R
Br J Dermatol; 2023 Feb; 188(2):218-227. PubMed ID: 36763878
[TBL] [Abstract][Full Text] [Related]
12. Safety and Efficacy of Ritlecitinib and Brepocitinib in Alopecia Areata: Results from the Crossover Open-Label Extension of the ALLEGRO Phase 2a Trial.
King B; Guttman-Yassky E; Peeva E; Banerjee A; Zhu L; Zhu H; Cox LA; Vincent MS; Sinclair R
JID Innov; 2022 Nov; 2(6):100156. PubMed ID: 36277481
[TBL] [Abstract][Full Text] [Related]
13. Integrated Safety Analysis of Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis From the Phase II and Phase III Clinical Trial Program.
Simpson EL; Silverberg JI; Nosbaum A; Winthrop KL; Guttman-Yassky E; Hoffmeister KM; Egeberg A; Valdez H; Zhang M; Farooqui SA; Romero W; Thorpe AJ; Rojo R; Johnson S
Am J Clin Dermatol; 2021 Sep; 22(5):693-707. PubMed ID: 34406619
[TBL] [Abstract][Full Text] [Related]
14. Evaluating the Therapeutic Potential of Ritlecitinib for the Treatment of Alopecia Areata.
Ramírez-Marín HA; Tosti A
Drug Des Devel Ther; 2022; 16():363-374. PubMed ID: 35210753
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of PF-06651600 (Ritlecitinib), a Novel JAK3/TEC Inhibitor, in Patients With Moderate-to-Severe Rheumatoid Arthritis and an Inadequate Response to Methotrexate.
Robinson MF; Damjanov N; Stamenkovic B; Radunovic G; Kivitz A; Cox L; Manukyan Z; Banfield C; Saunders M; Chandra D; Vincent MS; Mancuso J; Peeva E; Beebe JS
Arthritis Rheumatol; 2020 Oct; 72(10):1621-1631. PubMed ID: 32419304
[TBL] [Abstract][Full Text] [Related]
16. Tofacitinib for the Treatment of Ulcerative Colitis: An Integrated Summary of up to 7.8 Years of Safety Data from the Global Clinical Programme.
Sandborn WJ; D'Haens GR; Sands BE; Panaccione R; Ng SC; Lawendy N; Kulisek N; Modesto I; Guo X; Mundayat R; Su C; Vranic I; Panés J
J Crohns Colitis; 2023 Apr; 17(3):338-351. PubMed ID: 36124702
[TBL] [Abstract][Full Text] [Related]
17. Oral Ritlecitinib and Brepocitinib for Moderate-to-Severe Ulcerative Colitis: Results From a Randomized, Phase 2b Study.
Sandborn WJ; Danese S; Leszczyszyn J; Romatowski J; Altintas E; Peeva E; Hassan-Zahraee M; Vincent MS; Reddy PS; Banfield C; Salganik M; Banerjee A; Gale JD; Hung KE
Clin Gastroenterol Hepatol; 2023 Sep; 21(10):2616-2628.e7. PubMed ID: 36623678
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of oral ritlecitinib for the treatment of active nonsegmental vitiligo: A randomized phase 2b clinical trial.
Ezzedine K; Peeva E; Yamaguchi Y; Cox LA; Banerjee A; Han G; Hamzavi I; Ganesan AK; Picardo M; Thaçi D; Harris JE; Bae JM; Tsukamoto K; Sinclair R; Pandya AG; Sloan A; Yu D; Gandhi K; Vincent MS; King B
J Am Acad Dermatol; 2023 Feb; 88(2):395-403. PubMed ID: 36370907
[TBL] [Abstract][Full Text] [Related]
19. Safety of Janus Kinase inhibitors in Patients with Alopecia Areata: A Systematic Review.
Papierzewska M; Waśkiel-Burnat A; Rudnicka L
Clin Drug Investig; 2023 May; 43(5):325-334. PubMed ID: 37138134
[TBL] [Abstract][Full Text] [Related]
20. Target Occupancy and Functional Inhibition of JAK3 and TEC Family Kinases by Ritlecitinib in Healthy Adults: An Open-Label, Phase 1 Study.
Martin DA; Telliez JB; Pleasic-Williams S; Zhang Y; Tierney B; Blatnik M; Gale JD; Banfield C; Zhou Y; Lejeune A; Zwillich SH; Stevens E; Tiwari N; Kieras E; Karanam A
J Clin Pharmacol; 2024 Jan; 64(1):67-79. PubMed ID: 37691236
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]